Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth
Intelligent Bio Solutions (Nasdaq: INBS) reported fiscal 2026 first quarter results for the period ended September 30, 2025, delivering record quarterly revenue of $1,111,797, up 32% sequentially and 28% year‑over‑year. Cartridge consumable sales totaled $640,300, representing 57.59% of revenue. Gross profit margin improved by 690 basis points to 46.6%, attributed to operational efficiency and a higher mix of cartridge sales. The company added 33 net new customer accounts (total active accounts: 492 across 24+ countries), secured a multi‑site contract in London covering 4,400 staff, launched the SmarTest Patch, and signed a global distribution agreement with SMARTOX for markets outside the U.S. and Canada.
Management highlighted consumable‑led recurring revenue momentum and margin expansion while advancing toward planned FDA clearance and U.S. market entry.
Intelligent Bio Solutions (Nasdaq: INBS) ha riportato i risultati del primo trimestre fiscale 2026 per il periodo terminato il 30 settembre 2025, registrando un record di fatturato trimestrale di $1,111,797, in crescita del 32% rispetto al trimestre precedente e del 28% annuo. Le vendite di consumabili per cartucce hanno totalizzato $640,300, rappresentando il 57,59% del fatturato. Il margine di utile lordo è migliorato di 690 punti base al 46,6%, attribuito all'efficienza operativa e a una maggiore composizione di vendite di cartucce. L'azienda ha aggiunto 33 nuovi account cliente (totale account attivi: 492 in oltre 24 Paesi), ha assicurato un contratto multi-sito a Londra che copre 4.400 dipendenti, ha lanciato lo SmarTest Patch e ha firmato un accordo globale di distribuzione con SMARTOX per i mercati al di fuori degli Stati Uniti e del Canada.
La direzione ha sottolineato la momentum di ricavi ricorrenti guidati dai consumabili e l'espansione del margine mentre avanza verso l'approvazione FDA pianificata e l'ingresso nel mercato statunitense.
Intelligent Bio Solutions (Nasdaq: INBS) reportó los resultados del primer trimestre fiscal 2026 para el periodo que terminó el 30 de septiembre de 2025, registrando una facturación trimestral récord de $1,111,797, con un aumento secuencial del 32% y un incremento anual del 28%. Las ventas de consumibles para cartuchos totalizaron $640,300, representando el 57,59% de los ingresos. El margen de beneficio bruto mejoró en 690 puntos básicos hasta 46,6%, atribuido a la eficiencia operativa y a una mayor mezcla de ventas de cartuchos. La empresa añadió 33 nuevos clientes (total de cuentas activas: 492 en 24+ países), aseguró un contrato multi‑sitio en Londres que cubre 4,400 empleados, lanzó el SmarTest Patch y firmó un acuerdo global de distribución con SMARTOX para mercados fuera de EE. UU. y Canadá.
La dirección destacó la dinámica de ingresos recurrentes impulsados por consumibles y la expansión de márgenes mientras avanza hacia la aprobación de la FDA planificada e entrada al mercado estadounidense.
Intelligent Bio Solutions (나스닥: INBS)은 2025년 9월 30일로 종료된 회계연도 2026년 1분기 실적을 발표했고, 분기 매출이 기록적으로 $1,111,797를 기록했으며, 전분기 대비 32%, 전년 동기 대비 28% 증가했습니다. 카트리지 소모품 매출은 $640,300로 총매출의 57.59%를 차지했습니다. 총 이익률은 690bp 포인트 상승하여 46.6%로 개선되었고, 이는 운영 효율성과 카트리지 매출 혼합의 증가에 기인합니다. 회사는 33개의 순 신규 고객 계정을 추가했고(활성 계정 총합: 492개 이상 24개국에 분포), 런던에서 4,400명의 직원를 커버하는 다중 사이트 계약을 체결했고, SmarTest Patch를 출시했으며, 미국과 캐나다 외 시장에 대해 SMARTOX와 글로벌 유통 계약을 체결했습니다.
경영진은 소비재 주도 지속적 매출 흐름과 마진 확대에 주목했고, 예정된 FDA 승인을 향해 미국 시장 진출을 추진하고 있습니다.
Intelligent Bio Solutions (Nasdaq: INBS) a publié les résultats du premier trimestre comptable 2026 pour la période se terminant le 30 septembre 2025, affichant un chiffre d'affaires trimestriel record de 1 111 797 dollars, en hausse de 32 % par rapport au trimestre précédent et de 28 % sur un an. Les ventes de consommables pour cartouches se sont totalisées à 640 300 dollars, représentant 53,59 % du chiffre d'affaires. La marge bénéficiaire brute s'est améliorée de 690 points de base pour atteindre 46,6 %, attribuée à l'efficacité opérationnelle et à une plus forte part des ventes de cartouches. L'entreprise a ajouté 33 nouveaux comptes clients (nombre total de comptes actifs : 492 dans plus de 24 pays), sécurisé un contrat multi-site à Londres couvrant 4 400 employés, lancé le SmarTest Patch, et signé un accord de distribution mondial avec SMARTOX pour les marchés en dehors des États-Unis et du Canada.
La direction a souligné la dynamique de revenus récurrents axée sur les consommables et l'expansion des marges tout en progressant vers l'autorisation FDA prévue et l'entrée sur le marché américain.
Intelligent Bio Solutions (Nasdaq: INBS) berichtete über die Ergebnisse des Geschäftsjahres 2026 des ersten Quartals für den Zeitraum bis zum 30. September 2025 und verzeichnete rekordhohen Quartalsumsatz von 1.111.797 $, was einer sequenziellen Steigerung von 32% und einer Steigerung von 28% year over year entspricht. Der Verkauf von Verbrauchsmaterialien für Kartuschen belief sich auf 640.300 $, was 57,59% des Umsatzes ausmacht. Die Bruttogewinnmarge verbesserte sich um 690 Basispunkte auf 46,6%, bedingt durch Betriebseffizienz und eine höhere Mischung aus Kartuschenverkäufen. Das Unternehmen verzeichnete 33 netto neue Kundenkonten (insgesamt aktive Konten: 492 in 24+ Ländern), sicherte einen Multi-Site-Vertrag in London, der 4.400 Mitarbeiter umfasst, führte den SmarTest Patch ein und schloss eine globale Vertriebspartnerschaft mit SMARTOX für Märkte außerhalb der USA und Kanadas ab.
Das Management hob die konsumgesteuerte wiederkehrende Umsatzdynamik und die Margensteigerung hervor, während man auf die geplante FDA-Zulassung und den Markteintritt in den USA zusteuert.
Intelligent Bio Solutions (ناسداك: INBS) أعلنت عن نتائج الربع الأول من السنة المالية 2026 للمدة المنتهية في 30 سبتمبر 2025، محققة إيرادات ربع سنوية قياسية تبلغ 1,111,797 دولار، بارتفاع 32% مقارنة بالربع السابق و 28% على أساس سنوي. بلغت مبيعات consumables لِـ كارتريدجات $640,300، و< b>تمثل 57.59% من الإيرادات. تحسن هامش الربح الإجمالي بمقدار 690 نقطة أساس ليصل إلى 46.6%، ويرجع ذلك إلى الكفاءة التشغيلية وتزايد مزيج مبيعات الكارتريدجات. أضافت الشركة 33 عميلًا جديدًا (إجمالي الحسابات النشطة: 492 في أكثر من 24 دولة)، وأمنت عقدًا متعدد المواقع في لندن يغطي 4,400 موظف، أطلقت SmarTest Patch، ووقعت اتفاقية توزيع عالمية مع SMARTOX للأسواق خارج الولايات المتحدة وكندا.
وأبرزت الإدارة الزخم المتجدد في الإيرادات الناتج عن المستهلكات وتوسع الهامش مع المضي قدماً نحو موافقة FDA المخطط لها والدخول إلى السوق الأمريكية.
- Record quarterly revenue of $1.11M
- Revenue growth +28% YoY
- Sequential revenue increase of +32%
- Gross margin improved +690 bps to 46.6%
- Cartridge sales = 57.59% of revenue
- Added 33 new customer accounts (total 492)
- None.
Insights
Record quarterly revenue of
Revenue rose to
Growth in active accounts (+33 this quarter to 492 across 24+ countries) and a large London deployment covering 14 sites and over 4,400 staff provide concrete commercial validation. The addition of the SmarTest® Patch and the SMARTOX® global distribution agreement broaden the product mix and international reach, while the company continues work toward planned FDA clearance for U.S. market entry (
Risks and dependencies include sustaining cartridge sales as the primary growth engine and successfully advancing the regulatory pathway toward FDA clearance; both factors will materially affect U.S. market timing and scale. Watch quarterly recurring revenue from cartridges, customer‑account growth, margin trajectory, and any regulatory milestones for the next
Record quarterly revenue of
Gross profit margins increased 690 basis points year-over-year to
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2025.
The fiscal 2026 first quarter delivered record quarterly revenue of
"Our first quarter results show accelerating momentum of our business model and the growing market adoption internationally of our non-invasive drug screening technology," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "We achieved record quarterly revenue of
Key Financial and Operational Highlights
- Revenue of
$1,111,797 , up32% sequentially from the fiscal fourth quarter 2025 and28% year-over-year from the fiscal first quarter 2025. - Cartridge sales of
$640,300 represented57.59% of total revenue, up from51.1% in the fiscal first quarter of 2025, demonstrating the strength of the Company's recurring revenue model. - Gross profit margins increased to
46.6% from39.68% in the fiscal first quarter of 2025, reflecting improved operational efficiency and product mix optimization. - Added 33 new customer accounts during the quarter, bringing the Company's total number of active accounts to 492 across 24+ countries.
Strategic Market Expansion and Partnerships
- Secured a major contract with a London public transport operator covering 14 operational sites and over 4,400 staff, representing a significant scale deployment.
- Expanded product portfolio with the addition of the SmarTest® Patch, an innovative 7-10 day continuous drug monitoring solution.
- Established a global distribution agreement with SMARTOX® to bring its SmarTest Patch technology to international markets outside of the U.S. and Canada.
"As our first fiscal quarter results show, the financial discipline implemented throughout fiscal 2025 is now translating into meaningful margin expansion and operational leverage," said Spiro Sakiris, CFO at Intelligent Bio Solutions. "We are seeing strong returns on strategic investments, with improved customer acquisition metrics and accelerating revenue per account. We believe that we are well positioned to capitalize on the growth opportunities ahead."
INBS's proprietary fingerprint technology addresses key pain points in drug screening, including privacy and dignity, user experience, and operational efficiency, positioning the Company to capitalize on the growing demand for non-invasive, rapid drug screening solutions. The addition of the SmarTest® Patch and SMARTOX® partnership, combined with INBS's international expansion and proven ability to secure large-scale deployments, positions the Company for continued revenue diversification and market growth throughout fiscal 2026.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit https://ibs.inc/
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
| Intelligent Bio Solutions Inc. Condensed Consolidated Balance Sheets | ||||||||
| As of September 30, | As of June 30, | |||||||
| 2025 | 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 1,660,105 | $ | 1,019,909 | ||||
| Accounts receivable, net | 717,823 | 594,614 | ||||||
| Inventories | 628,177 | 635,215 | ||||||
| Research and development tax incentive receivable | 924,062 | 734,408 | ||||||
| Assets held for sale | 66,020 | 327,500 | ||||||
| Other current assets | 488,182 | 826,976 | ||||||
| Total current assets | 4,484,369 | 4,138,622 | ||||||
| Property and equipment, net | 271,745 | 251,325 | ||||||
| Operating lease right-of-use assets | 1,808,892 | 69,520 | ||||||
| Intangibles, net | 3,473,303 | 3,790,319 | ||||||
| Total assets | $ | 10,038,309 | $ | 8,249,786 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expenses | $ | 3,992,427 | $ | 4,534,246 | ||||
| Current portion of operating lease liabilities | 362,801 | 84,659 | ||||||
| Current employee benefit liabilities | 567,059 | 534,990 | ||||||
| Notes payable | 139,787 | 197,146 | ||||||
| Total current liabilities | 5,062,074 | 5,351,041 | ||||||
| Employee benefit liabilities, less current portion | 100,041 | 84,921 | ||||||
| Operating lease liabilities, less current portion | 1,449,265 | - | ||||||
| Total liabilities | 6,611,380 | 5,435,962 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders’ equity | ||||||||
| Common stock, | 90,985 | 73,230 | ||||||
| Treasury stock, at cost, 116 shares as of September 30, 2025 and June 30, 2025 | (1 | ) | (1 | ) | ||||
| Additional paid-in capital | 69,325,542 | 65,783,916 | ||||||
| Accumulated deficit | (65,516,071 | ) | (62,533,065 | ) | ||||
| Accumulated other comprehensive loss | (279,228 | ) | (327,944 | ) | ||||
| Total consolidated Intelligent Bio Solutions Inc. equity | 3,621,227 | 2,996,136 | ||||||
| Non-controlling interest | (194,298 | ) | (182,312 | ) | ||||
| Total shareholders’ equity | 3,426,929 | 2,813,824 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 10,038,309 | $ | 8,249,786 | ||||
| Intelligent Bio Solutions Inc. Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) | ||||||||
| Three Months Ended September 30, | ||||||||
| 2025 | 2024 | |||||||
| Revenue | $ | 1,111,797 | $ | 872,287 | ||||
| Cost of revenue (exclusive of amortization shown separately below) | (593,506 | ) | (525,486 | ) | ||||
| Gross profit | 518,291 | 346,801 | ||||||
| Other income | ||||||||
| Government support income | 193,267 | 126,128 | ||||||
| Operating expenses | ||||||||
| Selling, general and administrative expenses | (2,659,824 | ) | (1,949,016 | ) | ||||
| Development and regulatory approval expenses | (486,169 | ) | (948,752 | ) | ||||
| Depreciation and amortization | (303,378 | ) | (300,422 | ) | ||||
| Impairment of long-lived assets | (261,780 | ) | - | |||||
| Total operating expenses | (3,711,151 | ) | (3,198,190 | ) | ||||
| Loss from operations | (2,999,593 | ) | (2,725,261 | ) | ||||
| Other income (expense), net | ||||||||
| Interest expense | (3,903 | ) | (22,327 | ) | ||||
| Realized foreign exchange loss | - | (51 | ) | |||||
| Interest income | 8,504 | 52,840 | ||||||
| Total other income, net | 4,601 | 30,462 | ||||||
| Net loss | (2,994,992 | ) | (2,694,799 | ) | ||||
| Net loss attributable to non-controlling interest | (11,986 | ) | (9,166 | ) | ||||
| Net loss attributable to Intelligent Bio Solutions Inc. | $ | (2,983,006 | ) | $ | (2,685,633 | ) | ||
| Other comprehensive income (loss) | ||||||||
| Foreign currency translation gain | 48,716 | 216,355 | ||||||
| Total other comprehensive income | 48,716 | 216,355 | ||||||
| Comprehensive loss | (2,946,276 | ) | (2,478,444 | ) | ||||
| Comprehensive loss attributable to non-controlling interest | (11,986 | ) | (9,166 | ) | ||||
| Comprehensive loss attributable to Intelligent Bio Solutions Inc. | $ | (2,934,290 | ) | $ | (2,469,278 | ) | ||
| Net loss per share, basic and diluted | $ | (0.35 | ) | $ | (0.70 | ) | ||
| Weighted average shares outstanding, basic and diluted | 8,546,934 | 3,811,090 | ||||||
FAQ
What were Intelligent Bio Solutions (INBS) fiscal Q1 2026 revenues on Nov 12, 2025?
How much did INBS cartridge sales contribute to Q1 2026 revenue?
How did Intelligent Bio Solutions' gross margin change in fiscal Q1 2026?
What customer growth did INBS report for fiscal Q1 2026?
What commercial deals did INBS announce in Q1 2026 that affect revenue diversification?
What operational milestones did INBS disclose on Nov 12, 2025 regarding product expansion?
